Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 21Thoracic 7Genitourinary 5Breast 4Tumor-Agnostic 3Sarcoma 3Other solid neoplasm 3Other hematologic neoplasm 2Myeloid 2Gynecologic 2Plasma cell 1Lymphoid 1CNS 1

Conditions

Endometrial Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × pemigatinib × Gynecologic × Clear all
NCT04463771 2025-12-10

POD1UM-204

Incyte Corporation

Phase 2 Active not recruiting
206 enrolled
Gynecologic

Neoplasm Metastasis, Endometrial Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡